ABIOMED (NASDAQ:ABMD) had its price objective raised by research analysts at Leerink Swann from $200.00 to $265.00 in a note issued to investors on Friday. The brokerage currently has an “outperform” rating on the medical equipment provider’s stock. Leerink Swann’s target price points to a potential upside of 16.08% from the company’s previous close.
A number of other brokerages also recently commented on ABMD. SunTrust Banks initiated coverage on shares of ABIOMED in a research report on Friday, September 29th. They issued a “buy” rating and a $195.00 price objective for the company. BidaskClub downgraded shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. BTIG Research downgraded shares of ABIOMED from a “buy” rating to a “neutral” rating in a research report on Monday, October 16th. Jefferies Group lifted their price objective on shares of ABIOMED to $250.00 and gave the company a “buy” rating in a research report on Friday, January 12th. Finally, Zacks Investment Research raised shares of ABIOMED from a “sell” rating to a “buy” rating and set a $203.00 price objective for the company in a research report on Monday, October 30th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. ABIOMED has a consensus rating of “Buy” and a consensus price target of $210.50.
ABIOMED (ABMD) opened at $228.29 on Friday. ABIOMED has a 12-month low of $103.53 and a 12-month high of $229.05. The firm has a market cap of $10,094.07, a price-to-earnings ratio of 146.34, a P/E/G ratio of 3.01 and a beta of 0.15. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.84 and a quick ratio of 5.20.
ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.16. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The company had revenue of $132.80 million during the quarter, compared to the consensus estimate of $131.18 million. During the same quarter last year, the firm posted $0.20 EPS. The company’s quarterly revenue was up 28.9% on a year-over-year basis. equities analysts forecast that ABIOMED will post 2.41 EPS for the current year.
In related news, Director Dorothy E. Puhy sold 6,364 shares of ABIOMED stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $179.08, for a total transaction of $1,139,665.12. Following the completion of the sale, the director now owns 39,532 shares of the company’s stock, valued at approximately $7,079,390.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Michael G. Howley sold 10,000 shares of ABIOMED stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the sale, the vice president now directly owns 56,757 shares of the company’s stock, valued at approximately $10,139,070.48. The disclosure for this sale can be found here. Insiders own 7.00% of the company’s stock.
Several hedge funds have recently made changes to their positions in ABMD. Koch Industries Inc. boosted its holdings in shares of ABIOMED by 40,431.3% during the 2nd quarter. Koch Industries Inc. now owns 799,277 shares of the medical equipment provider’s stock worth $794,000 after buying an additional 797,305 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of ABIOMED by 102.0% during the 3rd quarter. Janus Henderson Group PLC now owns 1,076,829 shares of the medical equipment provider’s stock worth $181,553,000 after buying an additional 543,793 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of ABIOMED by 2,219.4% during the 3rd quarter. Wells Fargo & Company MN now owns 364,427 shares of the medical equipment provider’s stock worth $61,443,000 after buying an additional 348,715 shares during the period. American Century Companies Inc. boosted its holdings in shares of ABIOMED by 99.8% during the 3rd quarter. American Century Companies Inc. now owns 484,142 shares of the medical equipment provider’s stock worth $81,626,000 after buying an additional 241,868 shares during the period. Finally, FMR LLC bought a new stake in shares of ABIOMED during the 2nd quarter worth about $32,609,000. 90.75% of the stock is owned by institutional investors and hedge funds.
WARNING: This report was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://ledgergazette.com/2018/01/21/abiomed-abmd-pt-raised-to-265-00-at-leerink-swann.html.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.